<p>This article discusses normal bone remodelling and explains how this changes when cancer cells invade the bone. Denosumab is a new agent for the treatment of bone metastases that has a different mode of action from the bisphosphonates used traditionally to treat metastatic bone disease. The article goes on to outline the potential benefits of denosumab use for patients, health professionals and service delivery.</p>